Suggested remit: To appraise the clinical and cost effectiveness of pegvaliase within its marketing authorisation for treating phenylketonuria.
 
Status Proposed
Process STA 2018
ID number 1110

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
29 November 2018 The Department for Health and Social Care has asked NICE to carry out an appraisal of pegvaliase within its marketing authorisation for treating phenylketonuria. Following on from advice received from the company the timelines for this appraisal are to be confirmed, whilst the company await the outcome of an ongoing European trial (OPTIC Study). The evidence from this study is critical to provide the necessary health economic evidence that will strongly support the NICE appraisal. Further information regarding the scheduling of this appraisal will be provided in due course.
27 June 2018 (10:00) Scoping workshop (London)
10 May 2018 - 08 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance